Hepatitis D virus infection is highly prevalent in subgroups of individuals with intravenous drug use and those with high-risk sexual behaviour, study has reported. Its prevalence has also increased twofold over time in patients infected with hepatitis B virus.
Dietary glutamine supplements help improve gastrointestinal (GI) symptoms while restoring intestinal permeability to normal in patients who have irritable bowel syndrome with diarrhoea (IBS-D) with intestinal hyperpermeability after an enteric infection, suggesting that glutamine supplements may be effective for this group of patients.
The human monoclonal antibody bezlotoxumab may help reduce the incidence of recurrent Clostridium difficile infections (CDI) in patients with inflammatory bowel disease (IBD), according to a post-hoc analysis of data from previous studies.
Extending the induction treatment for Crohn’s disease with the anti-interleukin 23 (IL-23) antibody risankizumab intravenously increases both clinical response and remission, and continuing treatment with maintenance subcutaneous risankizumab further sustains remission up to week 52, a recent study shows.
The addition of pertuzumab to trastuzumab and chemotherapy did not significantly affect overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric or gastroesophageal junction cancer, according to the JACOB* trial.
History of legal termination of pregnancy (TOP) is the strongest predictor of perinatal maternal mortality among patients with acute fatty liver of pregnancy (AFLP), followed by total bilirubin and serum creatinine, according to a recent study.
In patients receiving foecal microbiota transplantation (FMT) for the treatment of Clostridium difficile infection (CDI), high levels of Candida albicans may be associated with poor outcomes, a recent study has shown.